Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Cited by (1,004)

Items 701–800 of 1,004

1. Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A Literature Review on Pathophysiology and Treatment
   Michael Romanos, Juan Martin Garcia Cordova, Jose L. Villamarin, Juan Diego Pazmino Zurita, Andres Acosta · 2026 · Diabetes Obesity and Metabolism
2. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis
   Koji Ogawa, Takashi Kobayashi, Jun‐ichi Furukawa, Hisatoshi Hanamatsu, Akihisa Nakamura, Kazuharu Suzuki, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Masato Nakai et al. · 2020 · Scientific Reports
3. Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome
   Ahmad Moolla, Jasper de Boer, David Pavlov, Amin Amin, ANGELA E. R. TAYLOR, Lorna C Gilligan, Beverly A. Hughes, John Denis Ryan, Eleanor J. Barnes, Zaki K Hassan-Smith et al. · 2020 · Alimentary Pharmacology & Therapeutics
4. Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
   Anna Roskilly, Amy Hicks, Eleanor Taylor, Rebecca L. Jones, Richard Parker, Ian A.C. Rowe · 2020 · Liver International
5. Quantitative magnetic resonance imaging for chronic liver disease
   Guilherme Moura Cunha, Patrick J. Navin, Kathryn Jane Fowler, Sudhakar Kundapur Venkatesh, Richard L. Ehman, Claude B. Sirlin · 2021 · British Journal of Radiology
6. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis
   Dimitrios A. Koutoukidis, Susan Ann Jebb, Jeremy Tomlinson, Jeremy Cobbold, Paul N Aveyard · 2021 · Clinical Gastroenterology and Hepatology
7. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis
   Hyun Woo Lee, Hyung‐Jun Kim, Eun Jin Jang, Chang‐Hoon Lee · 2021 · Respiration
8. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease
   Guangmin Zuo, Liping Xuan, Zhuojun Xin, Yu Xu, Jieli Lu, Yuhong Chen, Meng Dai, Di Zhang, Weiqing Wang, Mian Li et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
9. A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease
   Ahmad Hassan Ali, Gregory F. Petroski, Alberto A. Diaz‐Arias, Alhareth Al Juboori, Andrew A. Wheeler, Rama Ganga, J. Benjamin Pitt, Nicole Spencer, Ghassan M. Hammoud, R. Scott Rector et al. · 2021 · Journal of Clinical Medicine
10. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease
    Jagpreet Chhatwal, Ozden Onur Dalgic, Wanyi Chen, Sumeyye Samur, Emily D. Bethea, Jade Xiao, Chin Hur, Kathleen E. Corey, Rohit Seth Loomba · 2022 · JAMA Network Open
11. Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
    Luca V. C. Valenti, Armando Tripodi, Vincenzo La Mura, Serena Pelusi, Cristiana Bianco, Erica Scalambrino, Sara Margarita, Francesco Malvestiti, Luisa Ronzoni, Marigrazia Clerici et al. · 2022 · JHEP Reports
12. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study
    Yuya Seko, Hirokazu Takahashi, Hidenori Toyoda, Hideki Hayashi, Kanji Yamaguchi, Michihiro Iwaki, Masato Yoneda, Taeang Arai, Toshihide Shima, Hideki Fujii et al. · 2022 · Hepatology Research
13. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease
    Mayuko Chikamatsu, Hiroshi Watanabe, Yuhi Shintani, Ryota Murata, Masako Miyahisa, Ayano Nishinoiri, Tadashi Imafuku, Mei Takano, Nanaka Arimura, Koh‐ichi Yamada et al. · 2023 · Journal of Controlled Release
14. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis
    Russell Evan Rosenblatt, Amit Mehta, David B. Snell, Erika Marie. Hissong, Andrea Siobhan Kierans, Sonal Rajesh Kumar · 2018 · Digestive Diseases and Sciences
15. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
    Stephanie Liebig, Neele Stöckmann, Andreas Geier, Monika Rau, Jörn Markus Schattenberg, Matthias J. Bahr, Michael Peter Manns, Elmar Jaeckel, Klaus Schulze‐Osthoff, Heike Bantel · 2019 · Clinical and Translational Gastroenterology
16. Endotoxin Inflammatory Action on Cells by Dysregulated-Immunological-Barrier-Linked ROS-Apoptosis Mechanisms in Gut–Liver Axis
    Andrei Dumitru, Elena Matei, G. Cozaru, Anca Chisoi, L. Alexandrescu, R. Popescu, Mihaela Pundiche Butcaru, E. Dumitru, Sorin Rugină, C. Tocia · 2024 · International Journal of Molecular Sciences
17. Lactylation as a metabolic epigenetic modification: Mechanistic insights and regulatory pathways from cells to organs and diseases
    Cong Chen, Jie Wang, Xueying Zhu, Shan Zhang, Xiandun Yuan, Jun Hu, Chao Liu, Lanchun Liu, Zhenpeng Zhang, Jun Li · 2025 · Metabolism
18. Autophagy is involved in acetylshikonin ameliorating non-alcoholic steatohepatitis through AMPK/mTOR pathway
    Jiacheng Zeng, Banghao Zhu, Meiling Su · 2018 · Biochemical and Biophysical Research Communications
19. Management of nonalcoholic fatty liver disease in the Middle East
    Faisal M. Sanai, Faisal Abdulrahman Abaalkhail, Fuad A. Hasan, Muhammad H. Farooqi, Nawal Alnahdi, Zobair M. Younossi · 2020 · World Journal of Gastroenterology
20. A 3D Human Liver Model of Nonalcoholic Steatohepatitis
    Marion Duriez, Agnès Jacquet, Lucile Hoet, Sandrine Roche, Marie‐Dominique Bock, Corinne Rocher, Gilles Haussy, Xavier Vigé, Zsolt Böcskei, Tamara Slavnic et al. · 2020 · Journal of Clinical and Translational Hepatology
21. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease
    Cheryl Huang, Jun Jie Seah, Chin Kimg Tan, Jia Wen Kam, Jessica Juliana Tan, Eng Kiong Teo, Andrew Boon Eu Kwek, Yu Jun Wong, Malcolm Teck Kiang Tan, Tiing Leong Ang et al. · 2020 · Clinics and Research in Hepatology and Gastroenterology
22. Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study)
    Oumarou Nabi, Jérôme Boursier, Karine Lacombe, Philippe Mathurin, Victor de Lédinghen, Marcel Goldberg, Marie Zins, Lawrence Serfaty · 2021 · Digestive Diseases and Sciences
23. Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis
    Takeshi Okanoue, Toshihide Shima, Yasuhide Mitsumoto, Atsushi Umemura, Kanji Yamaguchi, Yoshito Itoh, Masato Yoneda, Atsushi Nakajima, Eishiro Mizukoshi, Shuichi Kaneko et al. · 2021 · Hepatology Research
24. Genetic risk scores and personalization of care in fatty liver disease
    Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca V. C. Valenti · 2021 · Current Opinion in Pharmacology
25. A gathering storm
    Nitin Kapoor, Jennifer Audsley, Priscilla Rupali, Joe J Sasadeusz, Thomas Vizhalil Paul, Nihal Thomas, Sharon R. Lewin · 2019 · AIDS
26. Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients
    Christoph Roderburg, Sarah Krieg, Andreas H. Krieg, Sascha Vaghiri, Raphael U. Mohr, Marcel Konrad, Mark Luedde, Tom Luedde, Karel Kostev, Sven Heiko Loosen · 2023 · Clinical Research in Cardiology
27. Epidemiology of NAFLD – Focus on diabetes
    Zobair M. Younossi, Linda L Henry · 2024 · Diabetes Research and Clinical Practice
28. Synergy of Phospholipid—Drug Formulations Significantly Deactivates Profibrogenic Human Hepatic Stellate Cells
    Gina Valentino, Cristina Zivko, Florian Weber, Lorine Brülisauer, Paola Luciani · 2019 · Pharmaceutics
29. Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score
    Stuart C. Gordon, Nandita Kachru, Emily D. Parker, Stephanie Korrer, Ahmet Burak Ozbay, Robert J. Wong · 2020 · Hepatology Communications
30. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care
    Wolf Peter Hofmann, Peter Buggisch, Lisa A. Schubert, Nektarios Dikopoulos, Jeannette Schwenzer, Marion Muche, Gisela Felten, Renate Heyne, Patrick Ingiliz, Anna Hartmann Schmidt et al. · 2020 · JHEP Reports
31. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
    Manuel Romero‐Gómez, Nandita Kachru, Meritxell Ascanio, Josep Darbà, Sanatan Shreay · 2020 · Medicine
32. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial
    Samer Gawrieh, Laura Wilson, Katherine P. Yates, Oscar W. Cummings, Eduardo Vilar‐Gómez, Veeral H. Ajmera, Kris V. Kowdley, William M. Rosenberg, James Tonascia, Naga Chalasani · 2021 · Hepatology Communications
33. The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastography
    Veeral H. Ajmera, Amy Y Liu, Ricki Bettencourt, Debanjan Dhar, Lisa Richards, Rohit Seth Loomba · 2021 · Alimentary Pharmacology & Therapeutics
34. Cancer and hepatic steatosis
    Rafael Paternostro, Wolfgang Sieghart, Michael A Trauner, Matthias Pinter · 2021 · ESMO Open
35. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis
    Shaya Noorian, Yejoo Jeon, Minh Thu T. Nguyen, Jenny S. Sauk, Berkeley N. Limketkai · 2021 · Inflammatory Bowel Diseases
36. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
    Naim Alkhouri, Monica A. Tincopa, Rohit Seth Loomba, Stephen A. Harrison · 2021 · Hepatology Communications
37. How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography—A Review of the Literature and Proposed Multistep Approach
    Mădălina-Gabriela Țâru, Lidia Neamți, Vlad Țâru, Lucia Maria Procopciuc, Bogdan Procopeț, Monica Lupșor‐Platon · 2023 · Diagnostics
38. Nanodrug Delivery Systems for Metabolic Chronic Liver Diseases: Advances and Perspectives
    Foteini Athanasopoulou, Michail Manolakakis, Santiago Vernia, Nazila Kamaly · 2023 · Nanomedicine
39. CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin et al. · 2023 · BMC Gastroenterology
40. Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
    Celia Martínez–Sánchez, Octavi Bassegoda, Hongping Deng, Xènia Almodóvar, Ainitze Ibarzábal, Ana de Hollanda, Raquel–Adela Martínez García de la Torre, Delia Blaya, Sílvia Ariño, Natalia Jiménez et al. · 2023 · JHEP Reports
41. Nonalcoholic fatty liver disease burden – Switzerland 2018–2030
    Nicolas Goossens, Stefano Bellentani, Andreas Cerny, Jean‐François Dufour, François R. Jornayvaz, Joachim C. Mertens, Alberto Moriggia, Beat Muellhaupt, Francesco Negro, Homie A. Razavi et al. · 2019 · Swiss Medical Weekly
42. Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
    Mari J. Jokinen, Panu K. Luukkonen · 2024 · Trends in Pharmacological Sciences
43. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis
    Biaoyang Lin, Yingying Ma, Shengjun Wu, Yunhua Liu, Longgen Liu, Lihua Wu · 2019 · OMICS A Journal of Integrative Biology
44. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease
    Luisa Vonghia, Mikhaïl A. Van Herck, Jonas Weyler, Sven Francque · 2019 · Frontiers in Immunology
45. Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Cyrielle Caussy, Lars Johansson · 2020 · Endocrinology Diabetes & Metabolism
46. FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients
    Nozomi Kawata, Hirokazu Takahashi, Shinji Iwane, Kanako Inoue, Motoyasu Kojima, Michiko Kohno, Kenichi Tanaka, Hitoe Mori, Hiroshi Isoda, Satoshi Oeda et al. · 2020 · Diabetology International
47. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography
    Toshifumi Tada, Takashi Nishimura, Masahiro Yoshida, Hiroko Iijima · 2020 · Journal of Medical Ultrasonics
48. Quantification of Liver Fat by MRI-PDFF Imaging in Patients with Suspected Non-alcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome, Liver Function Test and Ultrasonography
    Gajanan Ashokrao Rodge, Mahesh Kumar Goenka, Usha Goenka, Shivaraj Afzalpurkar, Bhavik Bharat Shah · 2020 · Journal of Clinical and Experimental Hepatology
49. Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury
    Nao Hasuzawa, Keita Tatsushima, Lixiang Wang, Masaharu Kabashima, Rie Tokubuchi, Ayako Nagayama, Kenji Ashida, Yoshihiro Ogawa, Yoshinori Moriyama, Masatoshi Nomura · 2021 · Scientific Reports
50. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma
    Marinela Krizanac, Paola Berenice Mass Sanchez, Ralf Weiskirchen, Anastasia Asimakopoulos · 2021 · International Journal of Molecular Sciences
51. Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease
    Vinod K. Rustgi, Steve Duff, Mohamed I. Elsaid · 2022 · Journal of Medical Economics
52. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes
    Nabil Noureddin, Mazen Noureddin, Amandeep Singh, Naim Alkhouri · 2021 · Digestive Diseases and Sciences
53. A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity
    Grit Zahn, Diana M. Willmes, Nermeen N. El-Agroudy, Christopher J. Yarnold, Richard Jarjes-Pike, Sabine Schaertl, Kay Schreiter, Wiebke Gehrmann, Andrea Wong, Tommaso Zordan et al. · 2022 · Metabolites
54. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
    Jihyun An, Joo Hyun Sohn · 2022 · Clinical and Molecular Hepatology
55. Nonalcoholic fatty liver disease from a primary care perspective
    Jeanne M. Clark, Donna R. H. Cryer, Michelle Morton, Jay H. Shubrook · 2023 · Diabetes Obesity and Metabolism
56. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
    Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idılman, Mesut Gümüşsoy, Diğdem Kuru Öz, Ayşe Erden et al. · 2023 · Hepatology
57. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)
    Tobias Puengel, Frank Tacke · 2023 · Expert Opinion on Investigational Drugs
58. MEFIB‐Index and MAST‐Score in the assessment of hepatic decompensation in metabolic dysfunction‐associated steatosis liver disease—Individual participant data meta‐analyses
    Nabil Noureddin, Veeral H. Ajmera, Jaclyn Bergstrom, Richele Bettencourt, Daniel Q. Huang, Harris Siddiqi, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi et al. · 2023 · Alimentary Pharmacology & Therapeutics
59. MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
    Wah‐Kheong Chan, Vincent Wai‐Sun Wong, Leon Anton Adams, Mindie H. Nguyen · 2024 · Hepatology International
60. Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD
    Sander Lefere, Antonella Mosca, Christian A. Hudert, Ellen Dupont, Emer Fitzpatrick, Eirini Kyrana, Anil Kumar Dhawan, Laura Kalveram, Andrea Pietrobattista, Anja M. Geerts et al. · 2024 · Hepatology
61. Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research
    Marcello Mancini, Paul Eugene Summers, Francesco Faita, Maurizia Rossana Brunetto, Francesco Callea, Andrea De Nicola, Nicole Di Lascio, Fabio Farinati, Amalia Gastaldelli, Bruno G. Gridelli et al. · 2018 · World Journal of Hepatology
62. A practical clinical approach to liver fibrosis
    Rahul Kumar, EK Teo, CH How, Tien Yin Wong, Tiing Leong Ang · 2018 · Singapore Medical Journal
63. Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy‐Confirmed Mouse Model of Advanced Non‐Alcoholic Steatohepatitis and Fibrosis
    Aimo Kannt, Efstathia Papada, Claire Kammermeier, Giuseppe D’Auria, Nuria Jiménez‐Hernández, Martin Stephan, Uwe Schwahn, Andreas Nygaard Madsen, Mette V. Østergaard, George V. Dedoussis et al. · 2019 · Molecular Nutrition & Food Research
64. Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
    Nabil Noureddin, Nedret Copur‐Dahi, Rohit Seth Loomba · 2024 · Alimentary Pharmacology & Therapeutics
65. Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study
    Guillaume Lassailly, Robert J. Caiazzo, Armelle Goemans, Mikaël Chetboun, Viviane Gnemmi, Julien Labreuche, Grégory Baud, Hélène Verkindt, Camille Marciniak, Naïma Oukhouya Daoud et al. · 2024 · Clinical Gastroenterology and Hepatology
66. The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD
    Minjuan Ma, Rui Duan, Hong Zhong, Tingming Liang, Li Guo · 2019 · Journal of Immunology Research
67. Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes
    Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐ho Lee, Young Dae Kim, Seung Up Kim · 2020 · Journal of Gastroenterology and Hepatology
68. Utility of Multiparametric CT for Identification of High-Risk NAFLD
    Meghan G. Lubner, Peter M. Graffy, Adnan Said, Rao F. Watson, Ryan D. Zea, Kyle M. Malecki, Perry Joseph Pickhardt · 2021 · American Journal of Roentgenology
69. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany
    Ali E. Canbay, Nandita Kachru, Jennifer Scarlet Haas, Dominic Meise, Ahmet Burak Ozbay, Jan‐Peter Sowa · 2021 · Annals of Translational Medicine
70. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy‐proven nonalcoholic fatty liver disease subjects
    Javier Ampuero, R. Aller, Rocío Gallego‐Durán, Javier Crespo, Javier Abad, Águeda González‐Rodríguez, Judith Gómez‐Camarero, Joan Caballería, Oreste Lo Iacono, Luis Ibáñez et al. · 2021 · Liver International
71. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study
    Helda Tutunchi, Fatemeh Naeini, Mehrangiz Ebrahimi‐Mameghani, Farzad Najafipour, Majid Mobasseri, Alireza Ostadrahimi · 2021 · Clinics and Research in Hepatology and Gastroenterology
72. Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
    Wile Balkhed, Fredrik O. Åberg, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias · 2022 · Liver International
73. FIB ‐4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: A Fine‐Gray competing risk analysis
    Andrew D. Schreiner, Jingwen Zhang, William P. Moran, David Koch, Justin E. Marsden, Sherry Livingston, Patrick D. Mauldin, Mulugeta Gebregziabher · 2022 · Liver International
74. Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients
    Gwyneth Shook Ting Soon, Feng Liu, Wei Qiang Leow, Aileen Wee, Lai Wei, Arun Jayant Sanyal · 2022 · Clinical Gastroenterology and Hepatology
75. Identification of high-risk subjects in nonalcoholic fatty liver disease
    Christiane Stern, Laurent Castéra · 2022 · Clinical and Molecular Hepatology
76. Advances in the Early Detection of Hepatobiliary Cancers
    Hasan Çağrı Yıldırım, Gözde Kavgacı, Elvin Chalabiyev, Ömer Dızdar · 2023 · Cancers
77. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
    Pin‐Nan Cheng, Wen‐Jone Chen, Charles Jia‐Yin Hou, Chih‐Lin Lin, Ming‐Ling Chang, Chia‐Chi Wang, Wei‐Ting Chang, Chao‐Yung Wang, Chun‐Yen Lin, Chung‐Lieh Hung et al. · 2023 · Clinical and Molecular Hepatology
78. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV
    Giovanni Guaraldi, Jovana Milić, Stefano Renzetti, Federico Motta, Felice Cinque, Jenny Bischoff, Andrea Dessilani, Jacopo Conti, Filippo Medioli, Martina Del Monte et al. · 2024 · AIDS
79. Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice
    Jiuyang Chang, Masahiro Koseki, Ayami Saga, Kotaro Kanno, Tomoaki Higo, Daisuke Okuzaki, Takeshi Okada, Hiroyasu Inui, Katsunao Tanaka, Masumi Asaji et al. · 2021 · Frontiers in Endocrinology
80. Advancements in MAFLD Modeling with Human Cell and Organoid Models
    Wang, Shi-Xiang, Yan, Ji-Song, Chan, Yun-Shen · 2022 · International Journal of Molecular Sciences
81. Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
    Fabio Colella, Neil Cowan Henderson, Prakash Ramachandran · 2025 · Journal of Clinical Investigation
82. Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
    Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Michael Trauner · 2025 · Hepatology
83. Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)
    Roberto Cannella, Amir Ali Borhani, MITCHELL E. TUBLIN, Jaideep Behari, Alessandro Furlan · 2019 · Abdominal Radiology
84. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications
    Theresa Hydes, Emily E. Brown, A. Hamid, Adrian Calvin Bateman, Daniel James Cuthbertson · 2021 · Clinical Therapeutics
85. Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis
    Yukihisa Fujinaga, Tadashi Namisaki, Hiroaki Takaya, Yuki Tsuji, Junya Suzuki, Akihiko Shibamoto, Takahiro Kubo, Satoshi Iwai, Fumimasa Tomooka, Soichi Takeda et al. · 2021 · Medicine
86. Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis
    Hannah P. Kim, Michael O. Idowu, Andrea R. Mospan, Andrew G. Allmon, Michael Roden, Philip Noel Newsome, Anna Suk-Fong Lok, Paul Joseph Thuluvath, JAWAHAR L. TAUNK, Michael W. Fried et al. · 2021 · Alimentary Pharmacology & Therapeutics
87. Prevalence and risk factors of metabolic-associated fatty liver disease during 2014–2018 from three cities of Liaoning Province: an epidemiological survey
    Lin Guan, Xinhe Zhang, Haoyu Tian, Xing Yu Jin, Hang Fan, Ningning Wang, Jing Sun, Dan Li, Jia Li, Xue Wang et al. · 2022 · BMJ Open
88. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease
    Shaojie Duan, Zhi-Ying Ren, Tao Zheng, Hongye Peng, Zuohu Niu, Hui Xia, Jia-Liang Chen, Yuan-Chen Zhou, Rong-Rui Wang, Shukun Yao · 2022 · World Journal of Gastroenterology
89. Phospholipid metabolism in the liver – Implications for phosphatidylserine in non-alcoholic fatty liver disease
    Marziyeh Anari, Magdalene K. Montgomery · 2023 · Biochemical Pharmacology
90. Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
    Wah Loong Chan, Shi-En Chong, Felicia Wen Si Chang, Lee Lee Lai, Kee Huat Chuah, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah‐Kheong Chan · 2023 · Hepatology International
91. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
    Ziwei Guo, Qinjuan Wu, Pengfei Xie, Jiuchong Wang, Wenliang Lv · 2024 · Frontiers in Immunology
92. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
    Nobuharu Tamaki, Shun‐ichi Wakabayashi, Takefumi Kimura, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Daniel Q. Huang, Takeji Umemura, Masayuki Kurosaki, Namiki Izumi · 2024 · Hepatology Research
93. Mechanisms of hepatic stellate cell activation as a therapeutic target for the treatment of non-alcoholic steatohepatitis
    Takuma Tsuchida · 2019 · Folia Pharmacologica Japonica
94. Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP‑1 cells
    Yuri Miyazoe, Satoshi Miuma, Hisamitsu Miyaaki, Yasuko Kanda, Suguru Nakashiki, Ryu Sasaki, Masafumi Haraguchi, Hidetaka Shibata, Takuya Honda, Naota Taura et al. · 2020 · Biomedical Reports
95. Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients
    Takuya Seike, Eishiro Mizukoshi, Kazutoshi Yamada, Hikari Okada, Masaaki Kitahara, Tatsuya Yamashita, Kuniaki Arai, Takeshi Terashima, Noriho Iida, Kazumi Fushimi et al. · 2020 · Journal of Gastroenterology
96. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection
    Thomas Krahn, Myriam Martel, Ruth Sapir‐Pichhadze, Nadine Kronfli, Julian Falutz, Giovanni Guaraldi, Bertrand Lebouché, Marina B. Klein, Philip Y.N. Wong, Marc Deschênes et al. · 2020 · The Journal of Infectious Diseases
97. Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
    Ryuichi Noguchi, Kosuke Kaji, Tadashi Namisaki, Kei Moriya, Hideto Kawaratani, Mitsuteru Kitade, Hiroaki Takaya, Yosuke Aihara, Akitoshi Douhara, Kiyoshi Asada et al. · 2020 · Molecular Medicine Reports
98. Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease
    Jérôme Boursier, Maéva Guillaume, Charlotte Bouzbib, Adrien Lannes, Raluca Pais, Sarra Smatti, Bertrand Cariou, Christophe Bureau, Nathalie Ganne‐Carrié, Marc Bourlière et al. · 2021 · Clinics and Research in Hepatology and Gastroenterology
99. Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes
    Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., Cuthbertson, D. J. · 2020 · Diabetic Medicine
100. CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
     Na Hu, Gang Yan, Maowen Tang, Yuhui Wu, Fasong Song, Xing Xia, Lawrence Chan, Pinggui Lei · 2023 · European Radiology Experimental